Clinical trials: Vasospasm;Peripheral
Pediatrics, Anesthesia
Papaverine vs Heparin for Peripheral Arterial Catheter Patency in Pediatric Patients
The purpose of this study is to compare intraoperative papaverine plus heparin to heparin alone for prevention of arterial spasm and maintenance of patency of peripheral arterial catheters during surgery in pediatric patients.
- Conditions
- Pediatrics, Anesthesia, Vasospasm
- Trial name
- NCT03894904
- Testing
- Papaverine, Heparin, Rescue papaverine, as needed
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- The University of Texas Health Science Center, Houston
Vasospasm;Peripheral, Burning
Dilution of Verapamil During Intraarterial Administration
This study will be a randomized, single-blind, prospective trial designed to evaluate the efficacy and safety of intra-arterial (IA) Verapamil diluted with normal saline compared to undiluted IA Nicardipine during transradial…
- Conditions
- Vasospasm;Peripheral, Burning, Pain
- Trial name
- NCT05625503
- Testing
- Verapamil, Nicardipine
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Illinois Chicago
Raynaud's Phenomenon
Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon
Raynaud's phenomenon (RP) is a disorder of the digital blood vessels resulting in episodic impairment of blood flow. During an attack of RP which commonly affects the hands and feet these arteries contract briefly which limits…
- Trial name
- REINO (NCT01315899)
- Testing
- ORM-12471 30mg, ORM-12471
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Orion Corporation, Orion Pharma
Cardiovascular Diseases, Metabolic Disease
Vascular Lab Resource (VLR) Biorepository
This is a study of biomarkers obtained from prospectively collected subject samples and their correlation with cardiovascular and metabolic diseases.
- Conditions
- Cardiovascular Diseases, Metabolic Disease, Peripheral Artery Disease, Carotid Disease
- Trial name
- NCT05628948
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- The Cleveland Clinic
Coronary Vasospasm
Endothelial Dysfunction and Coronary Artery Spasm
Non-obstructive coronary artery disease (NOCAD) frequently accounts for myocardial ischemia in women. Endothelial dysfunction is a pathogenic factor in coronary spastic angina (CSA).
- Trial name
- NCT00619294
- Where
- Japan
- Volunteers
- 158 people
- Sponsor
- Kumamoto University
Virtual Reality, Atherosclerosis
Coronary Angiography THerapeutic Virtual Reality
The CATH-VR study will investigate the effect of virtual reality (VR) on patient pain, anxiety, and radial artery vasospasm during coronary angiography.
- Conditions
- Virtual Reality, Atherosclerosis, Coronary Artery Disease, Anxiety
- Trial name
- CATH-VR (NCT03490903)
- Testing
- Virtual Reality, Fentanyl Injection, Midazolam injection
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Primary Raynaud's Phenomenon (PR), Genetic Mutations Causing PR
Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon
Vasospasm is a transient contraction causing a decrease in caliber of a vessel and thus a decrease in vascularization in a vascular territory leading to suffering of tissue in the sector concerned.
- Conditions
- Primary Raynaud's Phenomenon (PR), Genetic Mutations Causing PR, Study of Patients and Their Relatives (With or Without Primary PR)
- Trial name
- RAY-GENE (NCT02202291)
- Testing
- Demonstration of genetic mutations causing Raynaud's phenomenon
- Where
- 6 sites in France
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- Nantes University Hospital
Raynaud's Disease, Peripheral Vascular Disease
PF-00489791 For The Treatment Of Raynaud's
The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.
- Trial name
- NCT01090492
- Testing
- PF-00489791
- Where
- 55 sites in United States, Canada and 9 more
- Volunteers
- 243 people
- Sponsor
- Pfizer